MedPath

A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers

Completed
Conditions
Healthy
Interventions
Drug: Placebo
Registration Number
NCT02265718
Lead Sponsor
Pfizer
Brief Summary

The purpose of the study is to evaluate the difference in learning and performance measures associated with repeated use of an iPad video game (Akili Interactive's Project: EVO) in healthy elderly volunteers based on amyloid status.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
97
Inclusion Criteria
  • Healthy males and females between the ages of 70 and 80.
  • Subjects must have BMI of 17.5 to 32 kg/m2 and total body weight > 110 pounds.
  • Acceptable screening MRI and PET scans that pass quality control requirements.
Exclusion Criteria
  • Co-morbid diagnosis of clinically documented Alzheimer's disease; - Significant cognitive impairment;
  • MMSE (mini mental state examination) score <26

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
(Amyloid Negative)Ritalin-
(Amyloid Negative)Placebo-
Amyloid PositiveRitalin-
Amyloid PositivePlacebo-
Primary Outcome Measures
NameTimeMethod
divided attention performanceDay 0 - Day 28

The difference in effect of cognitive training on divided attention performance as measured by teh pre/post training change in interference cost on EVO dueal task assessment at Day 28.

Secondary Outcome Measures
NameTimeMethod
sustained attention, impulsivity and episodic memoryDay 0 - Day 28

The difference in effect of cognitive training on sustained attention, impulsivity and episodic memory as measured by the pre/post training change in performance at day 28

perforamce on EVO dual task assessment, TOVA and RAVLTDay 0 - Day 28

The performance on EVO dual task assessment, Test of Variables of Attention (TOVA and Rey Auditory Verbal Learning Test (RAVLT) as measured by the pre and post training scores at Day 0 and Day 28

within subject change on EVO, TOVA and RAVLTDay 0 - Day 28

The within subject change on EVO dual task assessment, TOVA and RAVLT between day -28 and Day 0.

Trial Locations

Locations (4)

Collaborative Neuroscience Network, LLC

🇺🇸

Long Beach, California, United States

Broward Research Group

🇺🇸

Hollywood, Florida, United States

Jasper Clinic, Inc.

🇺🇸

Kalamazoo, Michigan, United States

Miami Research Associates

🇺🇸

South Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath